Wollenberg B, Jan V, Schmit U M, Hofmann K, Stieber P, Fateh-Moghadam A
Department of Otorhinolaryngology, Head and Neck Surgery, Ludwig-Maximilians-University of Munich, Germany.
Anticancer Res. 1996 Sep-Oct;16(5B):3117-24.
CYFRA 21-1 was compared to the most reliable tumor markers for squamous cell carcinoma of the head and neck (HNSCC), SCC antigen and CEA. Sera of 163 patients with primary and 40 patients with recurrent HNSCC were examined. 94 patients with non-malignant ENT-diseases served as the control group. To give a specificity of 95% the cut-off-values were as follows: SCC: 1.9 ng/ml, CEA: 3.8 ng/ml, CYFRA 21-1: 2.9 ng/ml. SCC had the highest sensitivity at the time of primary diagnosis (P) at 43% and 61% at relapse (R), compared to CEA with P: 35%, R: 40% and CYFRA 21-1 with P: 17%, R: 18%. We show that CYFRA 21-1 cannot offer additional information to the clinical outcome of patients with HNSCC, whereas combined analysis of SCC and CEA leads to a markedly increased sensitivity of 60% at primary diagnosis and of 79% in cases of tumor relapse.
将细胞角蛋白19片段（CYFRA 21-1）与用于头颈部鳞状细胞癌（HNSCC）最可靠的肿瘤标志物鳞状细胞癌抗原（SCC）和癌胚抗原（CEA）进行了比较。检测了163例原发性HNSCC患者和40例复发性HNSCC患者的血清。94例患有非恶性耳鼻喉疾病的患者作为对照组。为达到95%的特异性，临界值如下：SCC为1.9纳克/毫升，CEA为3.8纳克/毫升，CYFRA 21-1为2.9纳克/毫升。在原发性诊断时，SCC的敏感性最高，为43%，复发时为61%；相比之下，CEA在原发性诊断时为35%，复发时为40%；CYFRA 21-1在原发性诊断时为17%，复发时为18%。我们发现CYFRA 21-1无法为HNSCC患者的临床结果提供额外信息，而SCC和CEA的联合分析在原发性诊断时敏感性显著提高至60%，肿瘤复发时提高至79%。
